Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Forecast & Target Price

View the latest analyst price targets and forecasts to stay informed on market expectations. Click here to open.

LBPH

Longboard Pharmaceuticals Inc

Nov 29 • 02:22PM ET

60.03

Dollar change +0.07
Percentage change 0.12	%

Healthcare • Biotechnology • USA • NASD

Peers: ACAD BMRN NBIX PTCT VRTX REGN BMY BIIB GILD AMGN

| Held by: VTI IWM VXF IWO SCHA VTWO XPH VHT IWC ARB

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.24	Insider Own	16.78%	Shs Outstand	39.05M	Perf Week	0.43%
Market Cap	2.34B	Forward P/E	-	EPS next Y	-2.82	Insider Trans	-0.76%	Shs Float	32.49M	Perf Month	0.55%
Income	-76.34M	PEG	-	EPS next Q	-0.63	Inst Own	88.94%	Short Float	5.94%	Perf Quarter	66.38%
Sales	0.00M	P/S	-	EPS this Y	6.87%	Inst Trans	-8.93%	Short Ratio	1.14	Perf Half Y	218.12%
Book/sh	7.05	P/B	8.51	EPS next Y	-26.89%	ROA	-42.91%	Short Interest	1.93M	Perf Year	1531.25%
Cash/sh	7.39	P/C	8.13	EPS next 5Y	-	ROE	-46.66%	52W Range	3.60 - 59.98	Perf YTD	895.52%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-27.40%	52W High	0.08%	Beta	1.03
Dividend TTM	-	Quick Ratio	15.97	Sales past 5Y	0.00%	Gross Margin	-	52W Low	1567.50%	ATR (14)	0.51
Dividend Ex-Date	-	Current Ratio	15.97	EPS Y/Y TTM	7.48%	Oper. Margin	0.00%	RSI (14)	79.95	Volatility	0.12% 0.30%
Employees	50	Debt/Eq	0.01	Sales Y/Y TTM	-	Profit Margin	-	Recom	2.43	Target Price	68.29
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	-14.38%	Payout	-	Rel Volume	0.51	Prev Close	59.96
Sales Surprise	-	EPS Surprise	-8.88%	Sales Q/Q	-	Earnings	Nov 07 AMC	Avg Volume	1.70M	Price	60.03
SMA20	0.41%	SMA50	16.59%	SMA200	87.08%	Trades		Volume	653,485	Change	0.12%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-10-24	Initiated	Truist	Buy	$60
Jul-01-24	Reiterated	Cantor Fitzgerald	Overweight	$60 → $90
May-01-24	Initiated	Robert W. Baird	Outperform	$36
Feb-16-24	Initiated	Citigroup	Buy	$40
Oct-24-23	Resumed	Cantor Fitzgerald	Overweight	$16 → $35
Apr-27-23	Initiated	B. Riley Securities	Buy	$13
Apr-07-21	Initiated	Evercore ISI	Outperform	$35
Apr-06-21	Initiated	Guggenheim	Buy	$27
Apr-06-21	Initiated	Citigroup	Buy	$37
Apr-06-21	Initiated	Cantor Fitzgerald	Overweight	$32

Nov-13-24 07:52AM	Longboard commences Phase III trial of bexicaserin for DEEs seizure treatment (Clinical Trials Arena)
Nov-12-24 08:30AM	Longboard Pharmaceuticals Initiates Phase 3 DEEp OCEAN Study Evaluating Bexicaserin in Developmental and Epileptic Encephalopathies (DEEs) (Business Wire)
Nov-07-24 04:01PM	Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates (Business Wire)
Oct-15-24 04:57PM	Health Care Roundup: Market Talk (The Wall Street Journal)
05:06AM	Lundbeck to acquire Longboard Pharmaceuticals for $2.6bn (Pharmaceutical Technology)
04:07PM	Loading…
Oct-14-24 04:07PM	Top 1% Biotech Longboard Scores A $2.6 Billion Deal And Skyrockets To A Record (Investor's Business Daily) +51.65%
03:45PM	Lundbeck to acquire Longboard Pharmaceuticals in $2.6B deal (Yahoo Finance Video)
09:39AM	Lundbeck to Buy Longboard Pharma in $2.6 Billion Deal (Bloomberg)
09:34AM	Why Is Epilepsy Focused Longboard Pharmaceuticals Stock Trading Higher On Monday? (Benzinga)
06:39AM	Denmark's Lundbeck bets on epilepsy drug with $2.6 billion Longboard deal (Reuters)
06:30AM	Lundbeck to Acquire Longboard Pharmaceuticals in a Strategic Deal, Significantly Enhancing Its Neuroscience Pipeline (Business Wire)
Oct-09-24 03:50PM	Longboard Pharmaceuticals Inc (LBPH) Q2 2024 Earnings Call Highlights: Promising Clinical ... (GuruFocus.com)
Oct-04-24 04:01PM	Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire) -7.92%
Sep-27-24 04:12AM	Longboard Pharmaceuticals begins Phase III Dravet syndrome trial (Clinical Trials Arena)
Sep-26-24 08:30AM	Longboard Pharmaceuticals Initiates Phase 3 DEEp SEA Study Evaluating Bexicaserin in Dravet Syndrome (Business Wire)
08:30AM	Loading…
Sep-19-24 08:30AM	Longboard Pharmaceuticals Receives Rare Pediatric Disease Designation and Orphan Drug Designation for Bexicaserin (LP352) in Dravet Syndrome (Business Wire) +13.95%
Sep-09-24 05:12AM	Longboard reports interim data from Phase II extension trial of DEEs treatment (Clinical Trials Arena)
Sep-08-24 06:30AM	Longboard Pharmaceuticals Announces Positive Interim Analysis Results from the Open-Label Extension (OLE) of the Phase 1b/2a PACIFIC Study Evaluating Bexicaserin in Participants with Developmental and Epileptic Encephalopathies (DEEs) (Business Wire)
Sep-06-24 04:01PM	Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire)
Aug-28-24 04:00PM	Longboard Pharmaceuticals to Participate in Four Upcoming Investor Conferences in September (Business Wire)
Aug-26-24 04:01PM	Longboard Pharmaceuticals to Present Late-Breaking and Encore Data at the 15th European Epilepsy Congress (Business Wire) +7.13% -5.55%
09:00AM	Longboard Pharmaceuticals to Host Investor & Analyst Event in New York on September 16, 2024 (Business Wire)
Aug-02-24 04:01PM	Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire)
Aug-01-24 04:01PM	Longboard Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates (Business Wire)
Jul-29-24 09:15AM	Longboard Pharmaceuticals to Report Second Quarter 2024 Financial Results and Host Corporate Update Call on August 1 (Business Wire) -6.74%
Jul-25-24 08:50AM	Longboard Pharmaceuticals (LBPH) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Jul-23-24 07:00AM	3 Russell 2000 Growth Stocks That Could Be Worth the Risk (Motley Fool) -8.65%
Jul-15-24 07:01PM	Andreas Halvorsen's Strategic Acquisition in Longboard Pharmaceuticals (GuruFocus.com)
Jul-09-24 09:55AM	Wall Street Analysts Think Longboard Pharmaceuticals (LBPH) Could Surge 43.7%: Read This Before Placing a Bet (Zacks) +8.23%
08:50AM	Longboard Pharmaceuticals (LBPH) is on the Move, Here's Why the Trend Could be Sustainable (Zacks)
04:00PM	Loading…
Jul-03-24 04:00PM	Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire) +9.28%
Jul-02-24 09:22AM	Longboard (LBPH) Up 14% as Epilepsy Drug Gets Breakthrough Tag (Zacks)
Jul-01-24 09:00AM	Longboard Pharmaceuticals Receives Breakthrough Therapy Designation for Bexicaserin (LP352) (Business Wire) +14.39%
Jun-10-24 09:00AM	Longboard Pharmaceuticals Announces Positive Interim Results from the Open-Label Extension (OLE) of the Phase 1b/2a PACIFIC Study Evaluating Bexicaserin in Participants with Developmental and Epileptic Encephalopathies (DEEs) (Business Wire)
Jun-03-24 04:01PM	Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire)
May-06-24 04:01PM	Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire) +7.01%
May-04-24 05:31AM	Longboard Pharmaceuticals Inc. (LBPH) Q1 2024 Earnings: Financial and Strategic Developments (GuruFocus.com)
May-03-24 10:10AM	Wedbush Adjusts Longboard Pharmaceuticals' PT to $34 From $32, Keeps Outperform Rating (MT Newswires) -6.29%
May-02-24 09:58PM	LBPH Stock Earnings: Longboard Pharmaceuticals Beats EPS for Q1 2024 (InvestorPlace)
04:01PM	Longboard Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Updates (Business Wire)
May-01-24 09:49AM	Starbucks downgraded, Dollar Tree upgraded: Wall Street's top analyst calls (The Fly)
07:07AM	Baird Starts Longboard Pharmaceuticals With Outperform Rating, $36 Price Target (MT Newswires)
Apr-03-24 09:00AM	Longboard Pharmaceuticals to Present Late-Breaking Data from the PACIFIC Study at the American Academy of Neurology (AAN) Annual Meeting on April 15 (Business Wire) -8.39%
Apr-02-24 04:00PM	Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire) -6.03%
Mar-14-24 05:31AM	Longboard Pharmaceuticals Inc Reports Full Year 2023 Financial Results (GuruFocus.com) -5.36%
Mar-12-24 04:01PM	Longboard Pharmaceuticals Reports Full Year 2023 Financial Results and Provides Corporate Updates (Business Wire) +5.05%
Mar-01-24 04:01PM	Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire)
Feb-02-24 04:30PM	Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire) -6.34%
Feb-01-24 08:30AM	Longboard Pharmaceuticals to Present at Two Upcoming Investor Conferences in February (Business Wire)
Jan-17-24 05:51AM	Forget the "Magnificent Seven" -- This Stock Has Nearly Quadrupled in 2024, and Wall Street Thinks It Can Go a Lot Higher (Motley Fool)
Jan-08-24 04:05PM	Longboard Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares (Business Wire) -5.77%
Jan-05-24 08:50AM	Recent Price Trend in Longboard Pharmaceuticals, Inc. (LBPH) is Your Friend, Here's Why (Zacks)
Jan-03-24 09:40PM	Longboard Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock (Business Wire) -10.76% +10.94%
09:19AM	Longboard Pharma (LBPH) Up on Upbeat Data From Epilepsy Study (Zacks)
Jan-02-24 04:37PM	Why Longboard Pharma Catapulted 316%, Leading A Biotech Stock Rally (Investor's Business Daily) +316.25%
04:01PM	Longboard Pharmaceuticals Announces Commencement of Public Offering of Common Stock (Business Wire)
01:06PM	Why Is Longboard Pharmaceuticals (LBPH) Stock Up 175% Today? (InvestorPlace)
08:00AM	Longboard Pharmaceuticals Announces Positive Topline Data from the PACIFIC Study, a Phase 1b/2a Clinical Trial, for Bexicaserin (LP352) in Participants with Developmental and Epileptic Encephalopathies (DEEs) (Business Wire)
Jan-01-24 04:47PM	Longboard Pharmaceuticals to Host Call to Discuss Topline Data from the PACIFIC Study, a Phase 1b/2a Clinical Trial for Bexicaserin (LP352) in Participants with Developmental and Epileptic Encephalopathies (DEEs) (Business Wire)
Nov-29-23 08:30AM	Longboard Pharmaceuticals Announces Initiation of First-in-Human Phase 1 Clinical Study of LP659 in Adult Healthy Volunteers (Business Wire)
Nov-24-23 09:35AM	Down -25.05% in 4 Weeks, Here's Why You Should You Buy the Dip in Longboard Pharmaceuticals, Inc. (LBPH) (Zacks)
Nov-21-23 04:00PM	Longboard Pharmaceuticals Presence at American Epilepsy Society (AES) Annual Meeting Reinforces Ongoing Commitment to the Rare Epilepsy Community (Business Wire)
Nov-14-23 05:05PM	FMR LLC Adjusts Stake in Longboard Pharmaceuticals Inc (GuruFocus.com)
Nov-13-23 02:46PM	Farallon Capital: A Global and Diversified Hedge Fund and its Top Stock Picks (Insider Monkey) -5.47%
Nov-08-23 09:55AM	Wall Street Analysts Believe Longboard Pharmaceuticals, Inc. (LBPH) Could Rally 262.45%: Here's is How to Trade (Zacks)
Nov-03-23 04:01PM	Longboard Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.07%
Nov-02-23 07:16PM	Longboard Pharmaceuticals Inc (LBPH) Reports Q3 2023 Financial Results (GuruFocus.com)
04:01PM	Longboard Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2023 Financial Results (Business Wire)
Nov-01-23 08:30AM	Longboard Pharmaceuticals to Present at Three Upcoming Investor Conferences in November (Business Wire)
Oct-05-23 04:05PM	Longboard Pharmaceuticals Announces Speakers for Investor & Analyst Event in New York on October 11, 2023 (Business Wire) +9.61% +5.58%
Sep-19-23 08:30AM	Longboard Pharmaceuticals to Host Investor & Analyst Event in New York on October 11, 2023 (Business Wire)
Aug-31-23 04:00PM	Longboard Pharmaceuticals to Participate in Three Upcoming Investor Conferences (Business Wire)
Aug-30-23 04:01PM	Longboard Pharmaceuticals to Present Data at Upcoming Medical Meetings (Business Wire) -6.65%
Aug-23-23 08:30AM	Longboard Pharmaceuticals Completes Enrollment of Phase 1b/2a PACIFIC Study Evaluating LP352 for the Treatment of Developmental and Epileptic Encephalopathies (Business Wire)
Aug-10-23 08:49AM	Institutional investors own a significant stake of 39% in Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) (Simply Wall St.)
Aug-03-23 04:01PM	Longboard Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2023 Financial Results (Business Wire) -5.47%
08:30AM	Longboard Pharmaceuticals to Present at Upcoming Investor Conferences (Business Wire)
Jun-26-23 04:00PM	Longboard Pharmaceuticals to Participate in Fireside Chat with Cantor on Friday, June 30, 2023 (Business Wire)
May-12-23 06:06AM	Will Longboard Pharmaceuticals (NASDAQ:LBPH) Spend Its Cash Wisely? (Simply Wall St.) -11.74%
May-09-23 04:00PM	Longboard Pharmaceuticals Provides Corporate Update and Reports First Quarter 2023 Financial Results (Business Wire) +5.90%
May-01-23 08:50AM	Longboard Pharmaceuticals, Inc. (LBPH) is on the Move, Here's Why the Trend Could be Sustainable (Zacks) -6.76%
Apr-14-23 08:50AM	Recent Price Trend in Longboard Pharmaceuticals, Inc. (LBPH) is Your Friend, Here's Why (Zacks) +5.74%
Apr-11-23 04:00PM	Longboard Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference (Business Wire) +6.38%
Apr-07-23 09:55AM	Does Longboard Pharmaceuticals, Inc. (LBPH) Have the Potential to Rally 208.22% as Wall Street Analysts Expect? (Zacks)
Apr-05-23 07:00AM	Societal CDMO Selected by Longboard Pharmaceuticals to Provide CDMO Services to Support Clinical Development of LP352 (GlobeNewswire)
Mar-07-23 09:55AM	Wall Street Analysts Predict an 184.81% Upside in Longboard Pharmaceuticals, Inc. (LBPH): Here's What You Should Know (Zacks) -5.24%
Mar-06-23 09:48AM	Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) Q4 2022 Earnings Call Transcript (Insider Monkey) +6.35%
Mar-02-23 04:01PM	Longboard Pharmaceuticals Reports Full Year 2022 Financial Results and Key Corporate Initiatives (Business Wire)
Feb-23-23 04:31PM	Longboard Pharmaceuticals to Report Full Year 2022 Financial Results and Key Corporate Initiatives on March 2, 2023 (Business Wire)
Feb-10-23 04:01PM	Longboard Pharmaceuticals Announces Closing of Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares in Public Offering of Common Stock (Business Wire)
Feb-07-23 09:03PM	Longboard Pharmaceuticals Announces Pricing of Public Offering of Common Stock (Business Wire)
04:13PM	Longboard Pharmaceuticals Announces Commencement of Public Offering of Common Stock (Business Wire)
Jan-14-23 08:00AM	Hedge funds investors have a lot riding on Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) with 27% ownership (Simply Wall St.)
Dec-05-22 08:30AM	Longboard Pharmaceuticals Announces Positive Topline Data from a Phase 1 Clinical Study Evaluating Central Nervous System Pharmacokinetics and Pharmacodynamics of LP352 in Healthy Volunteers (Business Wire) -8.57%
Nov-29-22 08:30AM	Longboard Pharmaceuticals Presence at American Epilepsy Society (AES) Annual Meeting Reinforces Ongoing Commitment to the Rare Epilepsy Community (Business Wire)
Nov-08-22 08:30AM	Longboard Pharmaceuticals to Present at Guggenheims Healthcare Talks 4th Annual Immunology and Neurology Day (Business Wire) +8.80%
Nov-03-22 08:30AM	Longboard Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2022 Financial Results (Business Wire) +8.47%
Oct-25-22 09:00AM	Is Longboard Pharmaceuticals (NASDAQ:LBPH) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Sep-29-22 04:01PM	Longboard Pharmaceuticals to Participate in the Cantor Neurology & Psychiatry Conference (GlobeNewswire)
Sep-01-22 04:01PM	Longboard Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire) +17.31%

Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for neurological diseases. The company was founded on January 3, 2020 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kaye Randall	CMO	Nov 19 '24	Option Exercise	6.00	30,554	183,324	48,474	Nov 19 08:13 PM
Lind Kevin Robert	CEO	Nov 13 '24	Option Exercise	3.12	12,808	40,002	443,740	Nov 13 08:48 PM
Kaye Randall	CMO	Oct 15 '24	Option Exercise	4.35	16,667	72,501	34,587	Oct 16 04:40 PM
Kaye Randall	CMO	Oct 15 '24	Sale	59.03	16,667	983,936	17,920	Oct 16 04:40 PM
Kaye Randall	CMO	Sep 16 '24	Option Exercise	4.35	16,666	72,497	34,586	Sep 16 07:36 PM
Kaye Randall	CMO	Sep 16 '24	Sale	31.64	16,666	527,318	17,920	Sep 16 07:36 PM
RANDALL KAYE	Officer	Sep 16 '24	Proposed Sale	34.32	33,333	1,143,989		Sep 16 04:35 PM
Lind Kevin Robert	CEO	Aug 12 '24	Option Exercise	3.15	82,482	259,995	430,932	Aug 13 06:03 PM
Kaye Randall	CMO	Aug 12 '24	Option Exercise	4.35	16,667	72,501	34,587	Aug 13 06:01 PM
Kaye Randall	CMO	Jan 23 '24	Buy	24.82	100	2,482	100	Aug 13 06:01 PM
Kaye Randall	CMO	Aug 12 '24	Sale	34.73	16,667	578,804	17,920	Aug 13 06:01 PM
Kaye Randall	CMO	Jun 25 '24	Sale	20.87	100	2,087	0	Aug 13 06:01 PM
RANDALL KAYE	Officer	Aug 12 '24	Proposed Sale	35.09	16,667	584,845		Aug 12 04:12 PM
ARENA PHARMACEUTICALS INC	Former 10% Owner	Jan 25 '24	Sale	24.25	3,978,540	96,479,595	0	Jan 29 04:37 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LBPH

Longboard Pharmaceuticals Inc

Upgrade your FINVIZ experience